Online inquiry

IVTScrip™ mRNA-Anti-IGF, MEDI-573(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11375MR)

This product GTTS-WQ11375MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IGF1&IGF2 gene. The antibody can be applied in Breast Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000618.5; NM_000612.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3479; 3481
UniProt ID P05019; P01344
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IGF, MEDI-573(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ11375MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5390MR IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CD58-Fc
GTTS-WQ13612MR IVTScrip™ mRNA-Anti-APP, R1450(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA R1450
GTTS-WQ2978MR IVTScrip™ mRNA-Anti-IL33, ANB020(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ANB020
GTTS-WQ15772MR IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA WX-G250
GTTS-WQ10240MR IVTScrip™ mRNA-Anti-MS4A1, LFB-R603(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA LFB-R603
GTTS-WQ11322MR IVTScrip™ mRNA-Anti-F, MEDI-524(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEDI-524
GTTS-WQ7096MR IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA FE 999301
GTTS-WQ11376MR IVTScrip™ mRNA-Anti-IGF, MEDI-573(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MEDI-573
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW